Characteristics of neutralizing antibodies to adenovirus capsid proteins in human and animal sera

Virology

Volumn 437, Issue 2, 2013, Pages 118-123

  Yu, Bin ^a   Dong, Jianing ^a   Wang, Chu ^a   Zhan, Yang ^a   Zhang, Haihong ^a   Wu, Jiaxin ^a   Kong, Wei ^a   Yu, Xianghui ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Adenovirus; Fiber; Knob; NAbs

Indexed keywords

CAPSID PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN; TRIMERIC KNOB PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ADENOVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SERUM; WESTERN BLOTTING;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BLOTTING, WESTERN; CAPSID PROTEINS; HUMANS; NEUTRALIZATION TESTS; SEROEPIDEMIOLOGIC STUDIES;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS; MIRIDAE;

EID: 84873726430     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.12.014     Document Type: Article

References (25)

1. Abbink P., Lemckert A.A., Ewald B.A., Lynch D.M., Denholtz M., Smits S., Holterman L., Damen I., Vogels R., Thorner A.R., O'Brien K.L., Carville A., Mansfield K.G., Goudsmit J., Havenga M.J., Barouch D.H. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 2007, 81(9):4654-4663.
2. Aste-Amezaga M., Bett A.J., Wang F., Casimiro D.R., Antonello J.M., Patel D.K., Dell E.C., Franlin L.L., Dougherty N.M., Bennett P.S., Perry H.C., Davies M.E., Shiver J.W., Keller P.M., Yeager M.D. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum. Gene Ther. 2004, 15(3):293-304.
3. Bauer U., Flunker G., Bruss K., Kallwellis K., Liebermann H., Luettich T., Motz M., Seidel W. Detection of antibodies against adenovirus protein IX, fiber, and hexon in human sera by immunoblot assay. J. Clin. Microbiol 2005, 43(9):4426-4433.
4. Bradley R.R., Lynch D.M., Iampietro M.J., Borducchi E.N., Barouch D.H. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J. Virol. 2012, 86(1):625-629.
5. Cheng C., Gall J.G.D., Nason M., King C.R., Koup R.A., Roederer M., McElrath M.J., Morgan C.A., Churchyard G., Baden L.R., Duerr A.C., Keefer M.C., Graham B.S., Nabel G.J. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J. Virol. 2009, 84(1):630-638.
6. Fender P., Kidd A.H., Brebant R., Oberg M., Drouet E., Chroboczek J. Antigenic sites on the receptor-binding domain of human adenovirus type 2 fiber. Virology 1995, 214(1):110-117.
7. Gahery-Segard H., Farace F., Godfrin D., Gaston J., Lengagne R., Tursz T., Boulanger P., Guillet J.G. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 1998, 72(3):2388-2397.
8. Havenga M.J., Lemckert A.A., Ophorst O.J., van Meijer M., Germeraad W.T., Grimbergen J., van Den Doel M.A., Vogels R., van Deutekom J., Janson A.A., de Bruijn J.D., Uytdehaag F., Quax P.H., Logtenberg T., Mehtali M., Bout A. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 2002, 76(9):4612-4620.
9. Hierholzer J.C., Stone Y.O., Broderson J.R. Antigenic relationships among the 47 human adenoviruses determined in reference horse antisera. Arch. Virol. 1991, 121(1-4):179-197.
10. Hong S.S., Habib N.A., Franqueville L., Jensen S., Boulanger P.A. Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J. Virol. 2003, 77(19):10366-10375.
11. Liebermann H., Lotz K., Mentel R., Bauer U., Seidel W. Mapping of linear epitopes on fibre knob of human adenovirus serotype 5. Virus Res. 2001, 73(2):145-151.
12. Liebermann H., Lotz K., Seidel W. Mapping of epitopes on the fiber knobs of human adenovirus serotypes 8 and 15. Intervirology 2002, 45(1):59-66.
13. Mast T.C., Kierstead L., Gupta S.B., Nikas A.A., Kallas E.G., Novitsky V., Mbewe B., Pitisuttithum P., Schechter M., Vardas E., Wolfe N.D., Aste-Amezaga M., Casimiro D.R., Coplan P., Straus W.L., Shiver J.W. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010, 28(4):950-957.
14. Norrby E. The structural and functional diversity of adenovirus capsid components. J. Gen. Virol. 1969, 5(2):221-236.
15. Piedra P.A., Poveda G.A., Ramsey B., McCoy K., Hiatt P.W. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 1998, 101(6):1013-1019.
16. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., Liu J., Thorner A.R., Swanson P.E., Gorgone D.A., Lifton M.A., Lemckert A.A., Holterman L., Chen B., Dilraj A., Carville A., Mansfield K.G., Goudsmit J., Barouch D.H. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441(7090):239-243.
17. Rux J.J., Burnett R.M. Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol. Ther. 2000, 1(1):18-30.
18. Sanchez J.L., Binn L.N., Innis B.L., Reynolds R.D., Lee T., Mitchell-Raymundo F., Craig S.C., Marquez J.P., Shepherd G.A., Polyak C.S., Conolly J., Kohlhase K.F. Epidemic of adenovirus-induced respiratory illness among US military recruits: epidemiologic and immunologic risk factors in healthy, young adults. J. Med. Virol. 2001, 65(4):710-718.
19. Sprangers M.C., Lakhai W., Koudstaal W., Verhoeven M., Koel B.F., Vogels R., Goudsmit J., Havenga M.J., Kostense S. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 2003, 41(11):5046-5052.
20. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., Lockman S., Peter T., Peyerl F.W., Kishko M.G., Jackson S.S., Gorgone D.A., Lifton M.A., Essex M., Walker B.D., Goudsmit J., Havenga M.J., Barouch D.H. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 2005, 174(11):7179-7185.
21. Walsh M.P., Seto J., Liu E.B., Dehghan S., Hudson N.R., Lukashev A.N., Ivanova O., Chodosh J., Dyer D.W., Jones M.S., Seto D. Computational analysis of two species C human adenoviruses provides evidence of a novel virus. J. Clin. Microbiol. 2011, 49(10):3482-3490.
22. Xia D., Henry L.J., Gerard R.D., Deisenhofer J. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7Å resolution. Structure 1994, 2(12):1259-1270.
23. Yeh H.Y., Pieniazek N., Pieniazek D., Gelderblom H., Luftig R.B. Human adenovirus type 41 contains two fibers. Virus Res. 1994, 33(2):179-198.
24. Yu B., Wang C., Dong J., Zhang M., Zhang H., Wu J., Wu Y., Kong W., Yu X. Chimeric hexon HVRs protein reflects partial function of adenovirus. Biochem. Biophys. Res. Commun. 2012, 421(2):170-176.
25. Yu B., Zhou Y., Wu H., Wang Z., Zhan Y., Feng X., Geng R., Wu Y., Kong W., Yu X. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. J. Med. Virol. 2012, 84(9):1408-1414.